|

Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial

RECRUITINGPhase 1Sponsored by Radboud University Medical Center
Actively Recruiting
PhasePhase 1
SponsorRadboud University Medical Center
Started2026-10-01
Est. completion2027-10-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors) for whom no approved conventional treatments are available.
* Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0).
* Measurable disease per RECIST 1.1
* ECOG performance status ≤ 2
* Negative pregnancy test within 7 days prior to starting the study in women of childbearing potential and adequate use of contraception.

Exclusion Criteria:

* Inability to provide informed consent
* Inability to obtain a (new) biopsy for molecular profiling
* Pregnancy or breastfeeding.
* Other active malignancies requiring therapy.
* Neutropenia (ANC \< 1.5 × 10⁹/L).
* Severe uncontrolled medical conditions (renal, cardiac, liver, respiratory).

Conditions5

Anaplastic Thyroid CancerCancerDifferentiated Thyroid CancerPoorly Differentiated Thyroid CarcinomaThyroid Cancer Stage IV

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.